Senate passes a “right to try” bill; Harm to patients comes next

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Patients for whom there are no existing treatments watch with desperation as a potentially helpful new drug spends years working its way from a lab bench, through clinical trials, and finally to the FDA, where reviewers consider it for approval.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Research associate, Division of Medical Ethics, NYU School of Medicine
Senior research associate, Division of Medical Ethics, NYU School of Medicine
Assistant professor in the Division, co-chair of NYU's Working Group on Compassionate Use and Pre-Approval Access.
In This Issue

YOU MAY BE INTERESTED IN

President Joe Biden’s proposed Advanced Research Projects Agency-Health would be a welcome partner to NCI—particularly in conducting large, collaborative clinical investigations, NCI Director Ned Sharpless said.“I think having ARPA-H as part of the NIH is good for the NCI,” Sharpless said April 11 in his remarks at the annual meeting of the American Association for Cancer Research. “How this would fit with the ongoing efforts in cancer at the NCI is still something to work out.”
Research associate, Division of Medical Ethics, NYU School of Medicine
Senior research associate, Division of Medical Ethics, NYU School of Medicine
Assistant professor in the Division, co-chair of NYU's Working Group on Compassionate Use and Pre-Approval Access.

Login